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Insulin and exercise stimulate glucose uptake into skel-
etal muscle via different pathways. Both stimuli converge
on the translocation of the glucose transporter GLUT4
from intracellular vesicles to the cell surface. Two Rab
guanosine triphosphatases-activating proteins (GAPs)
have been implicated in this process: AS160 for insulin
stimulation and its homolog, TBC1D1, are suggested to
regulate exercise-mediated glucose uptake into muscle.
TBC1D1 has also been implicated in obesity in humans
and mice. We investigated the role of TBC1D1 in glucose
metabolism by generating TBC1D12/2 mice and analyz-
ing body weight, insulin action, and exercise. TBC1D12/2
mice showed normal glucose and insulin tolerance, with
no difference in body weight compared with wild-type
littermates. GLUT4 protein levels were reduced by
∼40% in white TBC1D12/2 muscle, and TBC1D12/2 mice
showed impaired exercise endurance together with im-
paired exercise-mediated 2-deoxyglucose uptake into
white but not red muscles. These ﬁndings indicate that
the RabGAP TBC1D1 plays a key role in regulating GLUT4
protein levels and in exercise-mediated glucose uptake
in nonoxidative muscle ﬁbers.
Insulin and exercise enhance muscle glucose uptake by
triggering GLUT4 vesicles to translocate from within the
cell to the plasma membrane (PM) (1,2). These stimuli
activate different signaling pathways that converge on
similar steps in the GLUT4 trafﬁcking pathway. The
identiﬁcation of the Rab guanosine triphosphatase
(GTPase)-activating protein (GAP) AS160/TBC1D4 as an
Akt substrate was exciting because this provided a link
between insulin signaling and GLUT4 trafﬁcking (3).
RabGAPs regulate the activity of Rab GTPases, which
play an intimate role in eukaryotic vesicular trafﬁcking
(1,4). AS160 is localized to GLUT4 vesicles through its
interaction with insulin-responsive aminopeptidase (IRAP),
a constituent of GLUT4 vesicles (5–7). In the absence of
insulin, AS160 is thought to be active, thus facilitating
intracellular sequestration of GLUT4 by rendering the
Rab associated with GLUT4 vesicles, possibly Rab10, in-
active (8,9). Insulin stimulates Akt-dependent AS160
phosphorylation and 14-3-3 binding, leading to inactiva-
tion of AS160 GAP activity, increased GTP loading of
Rab10, and increased GLUT4 translocation to the PM
(1,10). Knockdown of AS160 in adipocytes increases PM
GLUT4 levels, consistent with the role of AS160 as a neg-
ative regulator (5,11,12).
TBC1D1 is a close homolog of AS160 that is highly
expressed in skeletal muscle and so has been postulated
to play a role in exercise-mediated GLUT4 trafﬁcking
(13–17). AS160 and TBC1D1 have identical domain struc-
tures. They share 47% amino acid identity and display
distinct tissue expression: AS160 is highly expressed in
heart, white adipose tissue (WAT), and oxidative muscles,
such as soleus, whereas TBC1D1 is expressed in muscle
but is absent from WAT (14). The suggested mechanism
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for TBC1D1 regulation is primarily based on the well-
known regulation of its close homolog AS160. TBC1D1
interacts with IRAP (18), inactivates the same Rabs as
AS160 (13), and binds 14-3-3 upon phosphorylation
(16,19). Although Akt mediates AS160 phosphorylation
on the crucial 14-3-3 binding sites, linking AS160 to in-
sulin signaling, TBC1D1 binds 14-3-3 in response to
AMPK activation, a kinase activated by exercise (2).
A mutation in TBC1D1 (R125W) is linked to human
obesity (20,21), although the precise role of this mutation
in TBC1D1 function is not known. Several mouse models
with reduced TBC1D1 expression have been described,
including a congenic model that contains a locus from
the Swiss Jim Lambert strain, and a gene trap knockout
(22–25). These mice show no change in body weight or
reduced body weight; reduced glucose uptake into isolated
white muscle in response to various agonists, including
insulin, contraction, or AICAR, an AMPK agonist; and in-
creased fatty acid oxidation at the whole-body level and
in muscle. In general, no defect in whole-body insulin-
mediated glucose metabolism was found (22–25).
We generated a TBC1D12/2 mouse model back-crossed
onto the C57Bl6 background for .10 generations. These
mice had no defect in whole-body insulin-mediated glucose
metabolism, unchanged body weight, and no difference in
high-fat diet (HFD)–induced obesity or insulin resistance
compared with wild-type (WT) littermates. They did, how-
ever, show impaired exercise endurance, which was likely
caused by impaired AMPK agonist–mediated glucose uptake
into muscle in vitro and impaired exercise-mediated glucose
uptake in vivo, highlighting the important role of TBC1D1
in exercise-regulated glucose metabolism in muscle.
RESEARCH DESIGN AND METHODS
Materials
General chemicals were from Sigma-Aldrich Chemical
Company, unless otherwise stated. Antibodies were from
Sigma-Aldrich (Flag), Cell Signaling Technology (TBC1D1,
AMPK, pT172 AMPK), Santa Cruz Biotechnology (14-3-3),
Mito Sciences (mito-proﬁle), Symansis (p642-AS160), and
Molecular Probes (cyclooxygenase, complex IV). Antibodies
against AS160 (5), GLUT4 (26), and GLUT1 (27) have been
previously described. BSA was obtained from Bovogen Bio-
logicals, and protease inhibitors were from Roche.
Generation of TBC1D12/2 mice
TBC1D12/2 mice were generated using a TBC1D1 gene-
trap ES cell line from BayGenomics (#RRR502). The gene-
trap vector insertion resulted in a truncated TBC1D1
mRNA. Heterozygous mice were generated by the Austra-
lian Phenomics Network ES to Mouse service at Monash
University. Mice were genotyped by PCR and real-time PCR
using the following primers within the gene-trap vector:
59-gcggcaccgcgcctttcggcgg-39 and 59-ggaagggctggtcttcatccac-39.
Mice were backcrossed onto C57Bl/6 background and
heterozygous (+/2) TBC1D1 breeding pairs produced
TBC1D12/2 and WT littermates for experiments. Mice
were group housed on a 12-h light/dark cycle with free
access to food and water. Mice were fed ad libitum a stan-
dard laboratory chow (8% of calories from fat) or a HFD
(Hugo’s Copha, 48% fat [7:1 lard-to-safﬂower oil ratio],
32% carbohydrate, 20% protein). All experimental proce-
dures were approved by the Garvan Institute/St Vincent’s
Hospital Animal Ethics Committee and followed the guide-
lines issued by the National Health and Medical Research
Council Australia.
Glucose and Insulin Tolerance Tests and Insulin
Measurements
Male littermates (12–16 weeks old) were fed standard
chow or the HFD for 4 weeks. Mice were fasted for 6 h
or overnight before glucose or insulin tolerance tests,
respectively. Glucose (1 g/kg) or insulin (1 unit/kg) was
administered by intraperitoneal injection, blood samples
were obtained from the tail, and glucose was measured
using an Accu-Chek Performa glucometer (Roche Diag-
nostics). Insulin was measured from whole blood using
an insulin ELISA kit (Crystal Chem).
In Vivo Electroporation
In vivo electroporation of DNA into mouse tibialis
anterior (TA) muscle was done under anesthesia, as
previously described (28). Brieﬂy, DNA was injected
into the TA muscle. Immediately after the injection, 8
pulses of 200 V/cm and 20 ms at 1 Hz were administered
across the distal limb via tweezer electrodes attached to
an ECM-830 electroporator (BTX).
Exercise Experiments
Exercise experiments were performed on an Exer3/6
mouse treadmill (Columbus Instruments) at a 5% incline.
Mice (15–21 weeks) underwent a 2-day period of tread-
mill running acclimatization that consisted of running for
15 min at a speed of 10 m/min on day 1 and for 15 min at
10 m/min, followed by 15 min at 13 m/min on day 2.
Exercise was performed as indicated until exhaustion, de-
ﬁned as falling off the treadmill three times within 15 s.
In Vitro Glucose Uptake Into Isolated Muscle
[3H]-2-deoxyglucose ([3H]-2DOG) uptake into isolated ex-
tensor digitorum longus (EDL) and soleus muscles was per-
formed as previously described (29). Muscles were incubated
in the absence or presence of 100 nmol/L insulin (Calbio-
chem) or 2 mmol/L 5-aminoimidazole-4-carboxamide
ribonucleotide (AICAR; Toronto Research Chemicals) for
20 min at 30°C.
Surgical Procedures and In Vivo Exercise-Mediated
Glucose Uptake
Mice were anesthetized with isoﬂurane anesthesia for
insertion of a polyurethane catheter into the left carotid
artery. The free catheter end was tunneled under the skin,
externalized at the neck, and sealed. Mice were then
singly housed and monitored daily. Catheters were
ﬂushed every 1–2 days with heparinized saline to main-
tain patency. At 5–8 days after surgery, mice were ﬁtted
with an extension catheter and run on a treadmill with
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speed gradually increasing to 16.5 m/min. [3H]-2DOG (0.2
mCi/kg) was administered via the catheter, and blood
samples were taken throughout the experiment. After
20 min, mice were killed and tissues removed and snap
frozen. Exercise-mediated glucose uptake into red and white
quadriceps was measured using AG 1-X8 Resin (BioRad)
to remove glucose 6-phosphate and measuring tracer in
the starting material (total [3H]-2DOG) and the ﬂow-
through (nonphosphorylated [3H]-2DOG) of the AG 1-X8
column, as previously described (30).
Quantitative Real-Time RT-PCR Assays
RNA extraction was performed using TRIZOL reagent
(Life Technologies, Carlsbad, CA), following the manu-
facturer’s protocol. Omniscript RT Kit (Qiagen) was
used for cDNA synthesis. Real-time RT-PCR analysis
was performed on Light Cycler 480 (Roche Applied Sci-
ence) with Universal Probe Master System. Primers and
probes for GLUT4 mouse gene were selected according
to the Universal Probe Library System (Roche Applied
Science). The Cyclophilin gene was used as a control. The
primers 59-gacggacactccatctgttg-39 and 59-gccacgatggagaca-
tagc-39 were used for GLUT4, and 59-ttcttcataaccacagt-
caagacc-39 and 59-accttccgtaccacatccat-39 were used for
Cyclophilin.
Glycogen Measurements
Glycogen was measured as described (31). Brieﬂy, tissues
were dissolved in 1 mol/L KOH, and glycogen was pre-
cipitated twice with 95% ethanol. The glycogen pellet was
resuspended in amyloglucosidase solution (0.3 mg/mL
amyloglucosidase in 0.25 mol/L acetate buffer [pH
4.75]) and incubated overnight at 37°C. Glucose was
determined using a calorimetric glucose oxidase kit
(ThermoFisher Scientiﬁc).
Triglyceride, Nonesteriﬁed Fatty Acids, and Lactate
Measurements
Calorimetric assays were performed according to the
manufacturer’s instructions to measure triglycerides
(Roche) and nonesteriﬁed fatty acids (NEFAs; Wako) in
plasma from mice. For lactate measurements, plasma was
deproteinized, and lactate was measured as previously
described (32,33).
Tissue Lysates, SDS-PAGE, and Immunoblotting
Mice were killed by cervical dislocation for tissue iso-
lation. Tissues were lysed (20 mmol/L HEPES [pH 7.4],
250 mmol/L sucrose, 1 mmol/L EDTA, 2% SDS, protease
inhibitors). Immunoblotting was carried out as previously
described (5). Quantiﬁcation of immunoblots was per-
formed using Odyssey IR imaging system software.
Statistical Analysis
Data are expressed as mean and SEM unless indi-
cated otherwise. P values were calculated by t test,
one-way ANOVA, or two-way ANOVA using GraphPad
Prism software.
RESULTS
GLUT4 Protein Levels Are Reduced in Muscle From
TBC1D12/2 mice
TBC1D12/2mice were generated using a gene-trap ES cell
line (Fig. 1). There was no detectable TBC1D1 protein in
muscles from TBC1D12/2 mice (Fig. 2A). The insertion of
the gene trap resulted in a putative truncated TBC1D1
construct, fused to b-galactosidase and neomycin trans-
ferase. However, this putative TBC1D1 truncation was
not detectable. AS160 protein levels were highest in heart,
soleus, WAT, and red quadriceps and very low in white
quadriceps, TA, and EDL. AS160 levels were not changed
in tissues from TBC1D12/2 mice compared with WT lit-
termates (Fig. 2A and B). GLUT4 levels were signiﬁcantly
reduced in muscle from TBC1D12/2 mice, with the most
pronounced decrease in muscles with low endogenous
AS160 expression. GLUT4 protein levels were signiﬁcantly
reduced in white quadriceps, TA, and EDL by 45%, 42%,
and 37%, respectively (Fig. 2A and B). No signiﬁcant change
occurred in GLUT4 mRNA in TA muscle between the geno-
types, indicating that reduced GLUT4 in TBC1D12/2 mus-
cle occurs posttranscriptionally (Fig. 2C), consistent with
recent ﬁndings (22–24). There was no compensatory upreg-
ulation in the level of GLUT1 (Fig. 2B).
TBC1D1 Overexpression Increases GLUT4 Protein
Levels
To determine if TBC1D1 expression can rescue GLUT4
levels, Flag-TBC1D1 cDNA was injected into the right leg
of mice, followed by in vivo electroporation. The left leg
was injected with empty vector. One week later, TA
Figure 1—TBC1D12/2mice genotyping. A: Diagram depicts endogenous protein and genomic DNA of WT and TBC1D12/2 (KO) location in
RRR502 ES cell line with predicted truncated TBC1D1 protein. b-geo, fusion of b-galactosidase and neomycin transferase; CaM, calmod-
ulin binding domain; pA, SV40 polyadenylation signal; PTB, phosphotyrosine binding domain; SA, splice acceptor site. B: TBC1D1 protein
and 14-3-3 loading control in TA muscle from WT and TBC1D1 KO mice.
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muscle lysates from left and right legs were immunoblot-
ted with antibodies against Flag, TBC1D1, and GLUT4.
Flag-tagged TBC1D1 was only detected in the TA muscle
from the right leg (Fig. 3A). The TBC1D1 antibody selec-
tively recognizes mouse but not human TBC1D1 and
therefore does not recognize the overexpressed TBC1D1.
GLUT4 levels were increased in TA that expressed
Flag-TBC1D1 compared with the control leg in WT and
TBC1D12/2 mice by 67% and 79%, respectively (Fig. 3A
and B).
TBC1D12/2 Mice Have Normal Insulin-Mediated
Glucose Metabolism and Body Weight
No difference was observed in glucose or insulin tolerance
between TBC1D12/2 and WT littermates (Fig. 4A and J).
In the insulin tolerance test for both genotypes, the glu-
cose levels increased initially before dropping, as previ-
ously reported (34), likely due to a stress response (Fig.
4J). There was no difference in body weight in mice fed
the chow or HFD, epididymal fat pad weight, fasting in-
sulin levels, insulin levels during glucose tolerance tests,
or glucose tolerance in response to the HFD between
TBC1D12/2 and WT mice (Fig. 4).
TBC1D12/2 Mice Show Impaired Exercise Endurance
We next examined the exercise performance of TBC1D12/2
mice compared with WT littermates. Mice were subjected
to exercise running on a treadmill, and two different ex-
ercise protocols were used to determine exercise endur-
ance as determined by the total running time during
low-intensity exercise, and maximal exercise capacity, de-
termined by maximal running speed during high-intensity
exercise. TBC1D12/2 mice showed a signiﬁcant impair-
ment in exercise endurance compared with WT littermates
(Fig. 5A and B), but not in maximal exercise capacity
(Fig. 5C).
There was no difference in muscle wet weight, mito-
chondrial oxidative phosphorylation protein levels, muscle
glycogen levels at rest or after exercise, plasma levels of
NEFA, and lactate between the genotypes (Fig. 6). There was
a signiﬁcant difference in plasma TGs between TBC1D12/2
and WT mice after exercise (Fig. 6C).
AMPK Agonist-Mediated Glucose Uptake Into Muscle
Is Impaired in TBC1D12/2 Mice
We next sought to examine whether the absence of
TBC1D1 affected insulin- or AMPK-induced glucose
uptake. EDL and soleus muscles were isolated from
TBC1D12/2 and WT littermates, mounted on muscle hold-
ers, and incubated in vitro. Muscles were incubated in the
absence or presence of insulin or the AMPK agonist AICAR,
and glucose uptake was measured using [3H]-2DOG tracer
accumulation (Fig. 7). [3H]-2DOG uptake was signiﬁ-
cantly reduced in EDL from TBC1D12/2 mice, but this
was not the case for soleus (Fig. 7A). This is likely due
to decreased GLUT4 levels in EDL from TBC1D12/2 mice
because insulin-stimulated AS160 phosphorylation was
Figure 2—GLUT4 protein levels are reduced in TBC1D12/2muscle.
Tissues from WT and TBC1D12/2 (KO) littermates were isolated
and immunoblotted with indicated antibodies. A: Representative
immunoblots are shown. B: Immunoblots were quantiﬁed and nor-
malized to WT protein levels. WT is shown in black bars and KO in
gray bars (n = 3–4). C: GLUT4 mRNA levels in TA of WT and TBC1D1
KO mice, normalized to WT (n = 3). RQ, red quadriceps; WQ, white
quadriceps. Error bars show the SEM. *P < 0.05, **P < 0.01.
Figure 3—TBC1D1 overexpression increases GLUT4 levels. A: In
vivo electroporation of endotoxin-free Flag-TBC1D1 (human) DNA
into right leg (R) and endotoxin-free empty vector DNA into left leg
(L) of WT and TBC1D12/2 (KO) mice. Mice were killed after 1 week,
tissues were isolated, and TA muscles were immunoblotted with
antibodies against Flag, TBC1D1, and GLUT4. Representative
immunoblots are shown. B: Quantiﬁcation of data in A (n = 3).
The error bars show the SEM. *P < 0.05.
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normal in these muscles (Fig. 7C). When [3H]-2DOG up-
take was analyzed as fold over basal, insulin signiﬁcantly
stimulated [3H]-2DOG uptake in EDL from WT and
TBC1D12/2 mice by 1.9- and 1.8-fold, respectively (Fig.
7B). In soleus muscle, insulin resulted in a 2.9-fold in-
crease in [3H]-2DOG uptake in WT and a 2.5-fold increase
in TBC1D12/2 mice. AICAR signiﬁcantly stimulated [3H]-
2DOG uptake by 1.6-fold in WT EDL and by 1.4-fold in
WT soleus. In contrast, AICAR-stimulated [3H]-2DOG
uptake was signiﬁcantly impaired in TBC1D12/2 muscles
compared with WT muscles, with no signiﬁcant increase
over basal [3H]-2DOG uptake. This was not due to defec-
tive AMPK activation because AICAR increased AMPK
phosphorylation in EDL to a similar extent in WT and
TBC1D12/2 mice (Fig. 7C). These data indicate that
TBC1D1 plays a speciﬁc role in AICAR-mediated but not
in insulin-dependent glucose uptake into white muscle.
Exercise-Mediated Glucose Uptake Is Reduced in
White Muscle of TBC1D12/2 Mice
The impairment in [3H]-2DOG uptake in response to
AICAR in TBC1D12/2 muscles indicates that impaired
glucose uptake might be the reason for the reduction in
exercise endurance observed in these mice. We next de-
termined [3H]-2DOG uptake into muscle during exercise
in WT and TBC1D12/2 mice. Because TBC1D12/2 and WT
mice had the same maximal exercise capacity (Fig. 5), they
were both exercised at the same speed of 16.5 m/min to
achieve the same relative exercise intensity. Mice from both
genotypes were able to complete the task. Exercise signiﬁ-
cantly increased [3H]-2DOG uptake into WT red quadriceps
by 15-fold and in white quadriceps by 8-fold (Fig. 8).
Notably, [3H]-2DOG uptake into white quadriceps was
6–8 times less than into red quadriceps (Fig. 8A). Although
[3H]-2DOG uptake into red quadriceps in TBC1D12/2
Figure 4—Chow- and HFD-fed TBC1D12/2 (KO) mice have glucose/insulin tolerance and body weights similar to those of their WT
littermates. WT and TBC1D1 KO mice (12–16 weeks) were studied at baseline (A–D) and after 4 weeks of the chow or HFD (E–G).
A: Baseline glucose tolerance test (GTT; n = 15–18). B: Insulin during glucose tolerance test (n = 9–10). C: Baseline body weight (n = 15–18).
D: Fasted (6-h fast) insulin (n = 11). E: Glucose tolerance test after 4 weeks of the chow or HFD (n = 5–7). F: Area under the curve (AUC) of
glucose tolerance test data in E. G: Weight gain on chow or HFD (%) (n = 6–9). H: Body weight of 6- to 23-week-old WT and KO mice (n =
25–30). I: Epididymal WAT weight (n = 8). J: Insulin tolerance test (ITT) (n = 6–7). Error bars show the SEM. *P < 0.05, **P < 0.01 vs. chow.
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mice was similar to that observed in WT mice, [3H]-2DOG
uptake into white quadriceps from TBC1D12/2 mice was
reduced by 54% (Fig. 8B).
DISCUSSION
Members of the RabGAP family have generated much
interest in the context of glucose metabolism. AS160
plays an important role in insulin-stimulated glucose
uptake in fat and muscle cells (1,35), and mutations in
AS160 are associated with severe insulin resistance in
humans (36,37). The AS160 homolog TBC1D1 is involved
in contraction-mediated glucose uptake (24) and has been
implicated in obesity (20,21). In the current study, we
show that TBC1D12/2 mice have no disruption in
whole-body insulin action but impaired exercise-regulated
metabolism. This is based on the following: 1) AICAR-
mediated [3H]-2DOG uptake into isolated muscle was im-
paired in TBC1D12/2 mice (Fig. 7), 2) exercise-mediated
[3H]-2DOG uptake into white quadriceps was signiﬁcantly
reduced in TBC1D12/2 mice in vivo (Fig. 8), and 3)
TBC1D12/2 mice exhibited reduced exercise endurance
(Fig. 5).
The impairment in exercise endurance in TBC1D12/2
mice (Fig. 5) clearly implicates TBC1D1 as having an im-
portant role in exercise-regulated glucose metabolism.
This defect could not be attributed to changes in muscle
weight, the levels of mitochondrial oxidative phosphory-
lation proteins, or plasma lactate or NEFA levels, or mus-
cle glycogen levels (Fig. 6), so it is likely due to the
impairment in the ability of the exercising white muscle
to import extracellular glucose (Fig. 8). White and red
muscle ﬁbers are both engaged during the treadmill exer-
cise used for this test because we observed a decline in
glycogen levels in both muscle types after a single bout of
exercise (Fig. 6), consistent with previous studies (38).
Although glucose uptake into white muscle was consider-
ably less than into red muscle (Fig. 8A), it is plausible that
the loss of TBC1D1 results in an impairment of glucose
uptake into speciﬁc ﬁbers that ultimately fatigue faster
and lead to an overall exercise impairment. These data
suggest that white muscle ﬁbers likely play a crucial role
even in endurance-style exercise and that a defect in these
ﬁbers may be a limiting factor in long-term endurance.
However, whether the defect in exercise-mediated glucose
uptake can be directly attributed to loss of TBC1D1 or the
parallel decrease in GLUT4 protein levels is unclear. The
greater defect we observed in AICAR compared with
insulin-dependent glucose uptake in EDL (Fig. 7) is con-
sistent with the defect being primarily due to loss of
TBC1D1. Given that TBC1D1 is a major AMPK substrate
in muscle (16,19,39), this would support the view that
AMPK is a major determinant of exercise-regulated glu-
cose metabolism in muscle. Although the role of AMPK in
exercise-mediated glucose uptake has been controversial
(40,41), a recent study demonstrated that muscle-speciﬁc
AMPK b1/b22/2 mice also display impaired exercise en-
durance (42).
Our data, combined with results of other studies, are
consistent with intramuscular energy stores, such as
phosphocreatine and glycogen, in providing the energy
needed during the initial phase of exercise, followed by
a gradually increasing reliance on extracellular glucose
when exercise is sustained. An impairment in this process
would appear to have a major effect on endurance, giving
rise to the concept that increased expression of TBC1D1
and/or AMPK might lead to improved endurance is
worthy of future study. One difference we observed
between WT and TBC1D12/2 mice after exercise, in ad-
dition to impaired exercise-mediated glucose uptake, was
a signiﬁcant reduction in plasma TG levels (Fig. 6). That
fatty acid oxidation is increased in the TBC1D12/2 mice
during exercise is possible, consistent with reports about
a switch in fuel usage in other TBC1D12/2 mouse models
(22,23). However, this is unlikely to be the cause of im-
paired endurance but rather a consequence of reduced
glucose uptake.
The lack of any detectable body weight phenotype in
TBC1D12/2 mice fed the chow or HFD (Fig. 4) was curi-
ous in light of previous studies (22–25). Initial studies
used a congenic strain containing a Swiss Jim Lambert
Figure 5—TBC1D12/2 mice have impaired exercise endurance. A: Survival plot showing the percentage of WT and TBC1D12/2 (KO)
littermates running at indicated times during an exercise endurance test (10 min at 10 m/min with an increase in running speed by 1 m/min
every 15 min). Total running time was determined until exhaustion. Individual data points are shown. B: Average and SEM of data shown in
A (n = 15–17). C: Maximal running speed of WT and TBC1D1 KO littermates was determined during a maximal exercise capacity test (start
at 8 m/min with an increase in running speed by 2 m/min every 1.5 min). Maximal running speed at exhaustion was determined (n = 15–17).
The error bars show the SEM. ***P < 0.001.
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locus with a mutation in the TBC1D1 gene that resulted
in reduced body weight on the HFD but not on chow
(24,25). A more recent study with the same mouse model
reported reduced body weight on a chow diet (22). How-
ever, a TBC1D12/2 gene-trap mouse model, similar to the
one used in our study, reported reduced body weight on
both chow and the HFD (23). The discrepancy in the body
weight phenotype is likely related to the mouse model
used, the breeding strategy used to generate mice for ex-
perimental use (i.e., use of littermates vs. nonlittermates),
the genetic background of the mice used, differences in the
age of onset of the HFD, duration of the HFD, and speciﬁc
composition (percentages and types of lipids) of the HFD.
Genetic background clearly plays a crucial role in metabo-
lism in mice (34), and it is now well recognized that breed-
ing strategies and the degree of backcrossing affect the
eventual metabolic phenotype. For this reason, all of our
metabolic studies were performed using mice that were
backcrossed onto a C57Bl/6 background for .10 genera-
tions, and all animals (TBC1D12/2 and WT) were litter-
mates obtained from TBC1D1+/2 breeding pairs.
We did, however, observe a signiﬁcant reduction in
GLUT4 levels in skeletal muscle from these mice (Fig. 2).
This likely involves an important role for TBC1D1 in
maintaining the stability of the GLUT4 protein, because
we did not observe any change in GLUT4 mRNA, consis-
tent with previous reports (22,24). The reduction in
GLUT4 levels could be rescued by overexpression of
TBC1D1 in TA muscle (Fig. 3). Notably, GLUT4 levels
were signiﬁcantly reduced only in muscle types that
expressed little AS160 (Fig. 2). This indicates that in
muscles expressing high levels of AS160, AS160
Figure 6—No difference in muscle tissue weights, mitochondrial
oxidative phosphorylation protein levels, or glycogen. A: TA, EDL,
and soleus were isolated and weighed from WT and TBC1D12/2
(KO) mice (n = 8). B: Muscle glycogen was measured in red quad-
riceps (RQ) and white quadriceps (WQ) from WT and TBC1D1 KO
littermates after resting or exercise (Ex) (treadmill running for 55 min:
10 min at 10 m/min with an increase in running speed by 1 m/min
every 15 min; n = 11–15). WT is shown in black bars and KO in gray
bars. C: TGs, lactate, and NEFAs were measured in plasma from
WT and TBC1D1 littermates after resting or exercise (see in B) (n =
5–8). D: Indicated tissues were immunoblotted for mitochondrial
oxidative phosphorylation proteins using a mito-proﬁle cocktail
that includes antibodies against subunits of complex II (C-II), com-
plex III (C-III), complex IV (C-IV), and complex V (C-V). Antibody
against 14-3-3 was used as a loading control (n = 3). Error bars
show the SEM. hr, hours. *P < 0.05, **P < 0.01.
Figure 7—AICAR-stimulated glucose uptake is impaired in
TBC1D12/2 muscle. Isolated EDL or soleus muscle from WT or
TBC1D12/2 (KO) littermates was incubated in the presence or ab-
sence (B) of 100 nmol/L insulin (I) or 2 mmol/L AICAR (A), and
[3H]-2DOG uptake was measured (n = 9–25). A: [3H]-2DOG uptake
is shown. B: [3H]-2DOG uptake data in A are presented as fold over
basal. C: EDL muscles were immunoblotted with indicated antibod-
ies. Error bars show the SEM. ns, not signiﬁcant. *P < 0.05 vs.
basal, ****P < 0.0001 vs. basal. #P < 0.0001 vs. WT. §P < 0.01
vs. WT. ‡P < 0.05 vs. WT.
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compensates for the loss of TBC1D1 in stabilizing GLUT4
levels in those muscles. Intriguingly, reduced GLUT4
levels have been observed in red muscle and fat from
AS1602/2 mice (43). This is consistent with a major
role for these RabGAPs in regulating intracellular reten-
tion of GLUT4 in intracellular vesicles. In the absence of
stimulation, TBC1D1 and AS160 are localized to GLUT4
vesicles via their interaction with IRAP. Under these cir-
cumstances, TBC1D1 and AS160 are nonphosphorylated,
and their GAP activity is likely on, thus maintaining a Rab
inactive. This leads to efﬁcient intracellular sequestration
of GLUT4. In the absence of TBC1D1 or AS160, GLUT4
vesicles are not efﬁciently sequestered, resulting in entry
of GLUT4 into the endocytic recycling system and ulti-
mately leading to increased delivery to the lysosome and
GLUT4 degradation. Consistent with this, the half-life of
the GLUT4 protein is;50 h in the absence of insulin, and
this is reduced to ;15 h in insulin-stimulated adipocytes
(44). Hence, we conclude that in the absence of TBC1D1,
GLUT4 protein levels are reduced in certain muscles that
are normally enriched in TBC1D1 but not in AS160 ex-
pression, possibly due to increased GLUT4 degradation.
Another question arising from the current studies is
why, in view of a 40% reduction in total GLUT4 levels
in muscle, did we not observe any signiﬁcant defect in
whole-body insulin action? Previous studies using muscle-
speciﬁc GLUT4+/2 mice observed a concomitant impair-
ment in glucose homeostasis and insulin action in muscle
(45). However, GLUT4 levels in these studies were re-
duced in all muscles, including oxidative type muscles,
whereas that was not the case in TBC1D12/2 mice. Given
that red muscles are much more insulin sensitive than
white muscles (46), this is consistent with a greater
contribution of red muscle to whole-body insulin action.
Importantly, insulin-stimulated glucose uptake was nor-
mal in isolated soleus from TBC1D12/2 mice (Fig. 7).
Although there was an absolute reduction in insulin-
stimulated [3H]-2DOG uptake into EDL from TBC1D12/2
mice compared with WT mice, likely due to the 40% re-
duction in GLUT4 protein levels (Fig. 2), it is important to
note that the fold increase over basal with insulin was
almost identical in TBC1D12/2 EDL and in WT EDL
(Fig. 7). Thus, it seems likely that the insulin-dependent
increase in muscle glucose uptake, combined with the
lesser contribution of white muscle to whole-body glucose
metabolism, contributed to normal whole-body glucose
and insulin tolerance in TBC1D12/2 mice (Fig. 4). This is
consistent with other studies using different TBC1D12/2
mouse models that also showed no defect in glucose and
insulin tolerance (22–24).
These studies provide further insights into the molec-
ular regulation of glucose metabolism in muscle during
exercise, implicating a key role for the RabGAP TBC1D1 in
this process. We have not, however, been able to observe
any signiﬁcant role for this protein in obesity or whole-
body insulin sensitivity.
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